Comparative efficacy and tolerability of carbamazepine and oxcarbazepine during long therapy of patients with bipolar and schizoaffective disorders

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 109, Issue 10, 2009, Pages 36-41

  Mosolov, S N ^a   Kostiukova, E G ^a   Ladyzhensky, M Y A ^a  

^a NONE

Author keywords

Bipolar affective disorder; Carbamazepine; Long therapy; Oxcarbazepine; Schizoaffective disorder

Indexed keywords

CARBAMAZEPINE; OXCARBAZEPINE;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77949446389     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. APA. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiat 2002; 159: Suppl 4: 1-50.
2. Arieff A.J. Et al. Hyponatraemia and death. or permanent brain damage in healthy children. Br Med J 1992; 304: 1218-1222.
3. Arnoldussen W., Hulsman J. Oxcarbazepine (OCBZ) twice daily is as effective as OCBZ three times daily: a clinical and pharmacokinetic study of 24 volunteeks and 6 patients. Abstract. Epilepsia 1991; 32: Suppl 1: 69.
4. Ballenger J.C., Post R.M. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978; 2: 159-175.
5. Ballenger J.C., Post R.M. Carbamazepine in manic - depressive illness: a new treatment. Am J Psychiat 1980; 137: 7: 782-790.
6. Bittencourt P.R.. Oxcarbazepine and spasticity: further observations. Arg Neuropsiquiatr 1988; 46: 4: 382-384.
7. Brodie M.J. Established anticonvulsants and treatment of refractory epilepsy. Lancet 1990; 336: 350-354.
8. Cabrera J.F., Muhlbauer H.D., Schley J. Et al. Long-term randomized clinical trial on oxcarbazepine vs.lithium in bipolar and schizoaffective disorders: preliminary results. Pharmacopsychiatry 1986; 19: 282-283.
9. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia. Raven Press, Ltd New York 1994; 23-25.
10. Dickinson R.G., Hooper W.D. Et al. Further clinical and pharmacokinetic observation on the new anticonvulsant, oxcarbazepine. Clin Exp Neurol 1988; 25: 127-133.
11. Dickinson R.G., Hooper W.D. Et al. First dose and steady state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabdite. Eur J Pharmacol 1989; 37: 69-74.
12. Dietrich D.E., Kropp S., Emrich H.M. Oxcarbazepine in affective and schizoaffective disorders. Pharmacopsychiatry 2001; 34: 242-250.
13. Dong X., Leppik I.E., White J. Et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65: 1976-1978.
14. Faigle J.W., Menge G.P. Pharmacokinetic and metabolic features of oxcar-bazepine and their clinical significance: comparison with carbamazepine. Int Clin Psychopharmacol 1990; 5: Suppl 1: 73-82.
15. Hartung U. Trileptal Tablets Divisible product profile summary. Ciba-Geigi Limited, CH-4002 Basle, Swizzeriand 1988; 15.
16. Hellewell J.S. Oxcarbazepine (Trileptal) in the treatment of bipolar disorders: a review of efficacy and tolerability. J Affect Disord 2002; 72: Suppl 1: S.23-34.
17. Mazza M., Marca G.D. Et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy & Behavior 2007; 10: 397-401.
18. Misdrahi D., Tournier M., Droulout T. Et al. Efficiency and safety of oxcarbazepine in mood disorders: A naturalistic study exploring the interest of plasma dosages. Eur Psychiat 2008; 23: 409-412.
19. Pendlebury S.C., Moses D.K., Eadie J. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol 1989; 8: 5: 337-344.
20. Raja M., Azzoni A. Oxcarbazepine vs. valproate in the treatment of mood and schizoafective disorders. Int J Neuropsychopharmacoly 2003; 6: 409-414.
21. Schutz H., Feldmann K.F. Et al. The metabo;ism of 14 C - oxcarbazepine in man. Xenobiotica 1986; 16: 8: 769-778.
22. Suppes T., Dennehy E.B., Swann A.C. Et al. For the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder (2000). J Clin Psychiat 2002; 63: 288-299.
23. Wang P.W., Ketter T.A. Pharmacokinetics of mood stabilizers and new anticonvulsants. Psychopharmacol Bull 2002; 36: 44-66.
24. Wildgrube C. Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders. Int Clin Psychopharmacol 1990; 5: Suppl 1: 89-94.